Table 4.

Odds ratios of hip fracture associated with ever use of hormone replacement therapy by route of administration and dose

AnyWithout progestinWith progestin
Use of hormone replacement therapyNo of cases/ controlsOdds ratio*No of cases/ controlsOdds ratio*No of cases/ controlsOdds ratio*
(95% CI)(95% CI)(95% CI)
Never used956/20731.0 (reference)956/20731.0(reference)956/20731.0(reference)
All:
Low dose16/400.82(0.45 to 1.51)15/291.02 (0.53 to 1.96)1/140.13 (0.02 to 1.03)
High dose80/3470.55 (0.41 to 0.73)46/1450.65 (0.46 to 0.94)49/2450.47 (0.33 to 0.69)
Tablet:97/3890.54 (0.41 to 0.71)59/1730.63 (0.45 to 0.88)55/2620.46 (0.32 to 0.67)
Low dose14/290.93 (0.48 to 1.80)13/241.05 (0.52 to 2.12)1/70.21 (0.02 to 1.77)
High dose65/3000.50 (0.36 to 0.68)31/980.61 (0.39 to 0.94)49/2450.47 (0.32 to 0.68)
Skin patch:23/940.62 (0.36 to 1.06)15/460.73 (0.38 to 1.40)12/600.49 (0.24 to 1.00)
Low dose3/120.47 (0.12 to 1.85)3/60.84 (0.18 to 3.82)0/70
High dose14/760.52 (0.28 to 0.98)7/360.49 (0.21 to 1.17)11/510.56 (0.27 to 1.18)
  • *Adjusted for age (50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 81 years) and the indication of hormone replacement therapy to prevent osteoporosis (yes/no).

  • †Equivalent to oestradiol <2 mg/day, conjugated oestrogens <0.625 mg/day, ethinyl oestradiol <10 μg/day, transdermal oestradiol <50 μg/day, or any oestradiol given by injection.

  • ‡Equivalent to oestradiol 2 mg/day, conjugated oestrogens 0.625 mg/day, ethinyl oestradiol 10 μg/day, transdermal oestradiol 50 μg /day, or any oestradiol given by injection.